title: [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
abstract: Eribulin gained its approval in March 2011 for the treatment of patients with locally advanced or metastatic breast cancer (MBC) whose disease has progressed despite anthracycline and taxane-containing regimens. This study retrospectively assessed the efficacy, safety and cost of this treatment for all patients with MBC treated by eribulin in Franche-Comté. Ninety-four patients received eribulin between July 2006 and October 2013. The median age was 62 years (35-83). Median overall survival was 10.3 months [95% CI: 7.6 to 17.9]. Median progression-free-survival was 3.8 months [95% CI: 2.9 to 5.0]. Clinical benefit was obtained in 55% evaluable patients [95% CI: 43.1 to 66.9] by RECIST criteria. Most common grade 3-4 adverse events (AEs) were neutropenia (38%), asthenia (10%) and peripheral neuropathy (7%). Median cost of the treatment was 9767 € per patient (6344-17,517). This analysis found similar results to the EMBRACE study despite less selected population. A medico-economic evaluation cost-utility type would assess the effectiveness of this strategy compared to standard treatments.
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France. Electronic address: mariejustine.paillard@gmail.com.
authors.forename: Marie-Justine
authors.initials: MJ
authors.lastname: Paillard
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France; Inserm U1098, 25000 Besançon, France; Université de Franche-Comté, SFR SMP, 25000 Besançon, France; EFS Bourgogne Franche-Comté, UMR1098, 25000 Besançon, France.
authors.forename: Elsa
authors.initials: E
authors.lastname: Curtit
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Erion
authors.initials: E
authors.lastname: Dobi
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Laura
authors.initials: L
authors.lastname: Mansi
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Fernando
authors.initials: F
authors.lastname: Bazan
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Cristian
authors.initials: C
authors.lastname: Villanueva
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Loïc
authors.initials: L
authors.lastname: Chaigneau
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Montcuquet
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Meneveau
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France; Inserm U1098, 25000 Besançon, France; Université de Franche-Comté, SFR SMP, 25000 Besançon, France; EFS Bourgogne Franche-Comté, UMR1098, 25000 Besançon, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Thiery-Vuillemin
authors.affiliation: Inserm U1098, 25000 Besançon, France; Université de Franche-Comté, SFR SMP, 25000 Besançon, France; CHU de Besançon, pôle pharmacie, 25000 Besançon, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Nerich
authors.affiliation: CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France; Inserm U1098, 25000 Besançon, France; Université de Franche-Comté, SFR SMP, 25000 Besançon, France; EFS Bourgogne Franche-Comté, UMR1098, 25000 Besançon, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pivot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001247:Asthenia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005663:Furans / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D012189:Retrospective Studies; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: Cancer du sein métastatique; Chemotherapy; Chimiothérapie; Cost; Coût; Eribulin; Metastatic breast cancer; Microtubule; Taxane; Éribuline